Evidence map›Paper›PMID 38988265›Full record

ArticleHaematologica2024

Excellent outcome of children/adolescents with primary mediastinal large B-cell lymphoma treated with a FAB/ LMB-based chemotherapy regimen with rituximab.

Marie Emilie Dourthe, Anne Auperin, Charlotte Rigaud, Melissa Barbati, Jacinthe Bonneau, Nimrod Buchbinder, Marie-Laure Couec, Peggy Dartigues, Stéphane Ducassou, Nathalie Garnier and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Marie Emilie DourtheDepartment of Pediatric Hematology and Immunology, Robert Debré University Hospital, AP-HP and University de Paris, Paris, France; Université Paris Cité, Institut Necker-Enfants Malades (INEM), Institut national de la santé et de la recherche médicale (Inserm) U1151, Paris. dourthe@aphp.fr.
Anne AuperinService de Biostatistique et d'Epidémiologie, Gustave Roussy Cancer Campus, INSERM U1018, CESP, Université Paris-Sud, Université Paris-Saclay, Villejuif.
Charlotte RigaudDepartments of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif.
Melissa BarbatiDepartment of Pediatric Oncology and Haematology, University Hospital of Lille, Lille.
Jacinthe BonneauDepartment of Pediatric Oncology and Haematology, University Hospital of Rennes, Rennes.
Nimrod BuchbinderDepartment of Pediatric Oncology and Haematology, University Hospital of Rouen, Rouen.
Marie-Laure CouecPediatric hematology and oncology department, University Hospital of Nantes, Nantes.
Peggy DartiguesDepartment of Biopathology, Morphology Unit, Gustave Roussy, Université Paris Saclay, Villejuif.
Stéphane DucassouDepartment of Pediatric Oncology and Haematology, University Hospital of Bordeaux, Bordeaux.
Nathalie GarnierInstitut d'Hématologie et d'Oncologie Pédiatrique, Hospices Civils de Lyon, Lyon.
Stéphanie HaouyDepartment of Pediatric Oncology and Haematology, University Hospital of Montpellier, Montpellier.
Bénédicte JoncaDepartment of nuclear medicine, University Hospital Tenon, Paris.
Anne JourdainDepartment of Pediatric Oncology and Haematology, University Hospital of Tours, Tours.
Amaury LerusteSIREDO Oncology Center, Institut Curie, PSL Research University, Paris.
Thierry MolinaDepartment of biopathology, University Hospital Necker Enfants Malades, Université Paris Cité, Paris.
Françoise MontraversDepartment of nuclear medicine, University Hospital Tenon, Paris.
Marlène PasquetDepartment of Pediatric Oncology and Haematology, University Hospital of Toulouse, Toulouse.
Aurélie PhulpinPediatric Oncology and Hematology Department, University Hospital of Nancy (CHRU Nancy), Nancy.
Maryline PoiréeDepartment of Pediatric Oncology and Haematology, University Hospital of Nice, Nice.
Mathieu SimoninPediatric Hematology Oncology Department, Sorbonne Université/Trousseau Hospital, APHP, Paris.
Alexandra SpiegelPediatric Hematology Oncology Department, University Hospital of Strasbourg, Strasbourg.
Arnauld VerschuurDepartment of Pediatric Hematology Immunology and Oncology, La Timone Hospital, APHM, Marseille.
Thierry LeblancDepartment of Pediatric Hematology and Immunology, Robert Debré University Hospital, AP-HP and University de Paris, Paris.
Judith Landman-ParkerPediatric Hematology Oncology Department, Sorbonne Université/Trousseau Hospital, APHP, Paris.
Catherine PatteDepartments of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif.
Véronique Minard-ColinDepartments of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; INSERM Unité 1015. veronique.minard@gustaveroussy.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38988265
PMCPMC11532712

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.